Monopar Therapeutics (MNPR) Net Equity Issued and Repurchased (2017 - 2024)

Monopar Therapeutics has reported Net Equity Issued and Repurchased for 6 years, with the latest figure at $1.0 million in Q4 2024.

• Quarterly Net Equity Issued and Repurchased rose 197.06% year-over-year to $1.0 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $1.0 million (down 71.42% YoY) and the FY2024 annual result came in at $4.2 million, up 102.6% from the prior year.
• Net Equity Issued and Repurchased rose to $1.0 million in Q4 2024 per MNPR's latest filing, from -$1.0 in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $10.9 million in Q1 2021 and troughed at -$1.0 in Q2 2024.
• A 5-year average of $2.0 million and a median of $657791.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2021 and 2024: Net Equity Issued and Repurchased jumped 2050.47% in 2021, then plunged 100.0% in 2024.
• Over 5 years, Net Equity Issued and Repurchased stood at $1.0 in 2020, then surged by 1092531100.0% to $10.9 million in 2021, then sank by 99.0% to $109337.0 in 2022, then jumped by 210.85% to $339870.0 in 2023, then jumped by 197.06% to $1.0 million in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $1.0 million, -$1.0, and $3.2 million for Q4 2024, Q2 2024, and Q1 2024 respectively.